The introduction of recombinant human erythropoietin (rHuEPO) in the early 1990s sparked a new capacity in performance enhancement primarily for endurance sports such as cycling and track and ...
Originally blood tests were introduced for medical reasons and for limiting misuse of recombinant human erythropoietin (rHuEPO). In this way it became possible to prevent athletes with haematocrit ...
Its product pipeline includes hCDR1 and rHuEPO. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback